Tokyo University of Agriculture and Technology

Tms Company LLC

Biogen Ma Inc.

Showa University

Ttc Co., Ltd.

National University Corporation Tokyo University of Agriculture and Technology

Keiji Hasumi

Keiko Hasegawa

Keita Shibata

Terumasa Hashimoto

Yoshikazu Kitano

Kazuo Honda

Hideo Ohishi

Haruki Koide

Ritsuko Narasaki

Eriko Suzuki

Yuuichi Nishimura

Naoko Nishimura

Kohta Tsujihara

Fumihiko Maeda

Kunitoshi Mitsumori

Kosuke Shimizu

Honda Kazuo

Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is &#x2014;CHY&#x2014;C(CH)Z, Y and Z are each independently &#x2014;H or &#x2014;OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less.

Cytoprotective agent

The invention provides a chroman derivative represented by the following Formula (I) that enables the production of an SMTP compound having a desired structure: 

Chroman derivative

Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is &#x2014;CHY&#x2014;C(CH)Z, Y and Z are each independently &#x2014;H or &#x2014;OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less. 

A triprenyl phenol compound represented by the following formula (II) and (III) and having a thrombolysis-enhancing activity, and an efficient method for producing the triprenyl phenol compound. In formula (II) and (III), Rrepresents an aromatic group having as a substituent or as a part of a substituent at least one member selected from the group consisting of a carboxyl group, a hydroxyl group, a sulfonic acid group and a secondary amino group, or an aromatic group which comprises a secondary amino group and may comprise nitrogen; Rin the general formula (III) represents an aromatic amino acid residue represented by the general formula (III-1) below; X represents &#x2014;CHY&#x2014;(CH)Z; and Y and Z are respectively &#x2014;H or &#x2014;OH or together form a single bond: (III-1) wherein Rrepresents a hydroxyl group which may be present or absent; and n represents an integer of 0 or 1. 

Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer

The present invention relates to a liver function ameliorant containing orniplabin as an active ingredient thereof.

Liver function ameliorant

The present invention provides a triprenyl phenol compound represented by the following formula (II) and (III) and having a thrombolysis-enhancing activity, and an efficient method for producing the triprenyl phenol compound. In formula (II) and (III), Rrepresents an aromatic group having as a substituent or as a part of a substituent at least one member selected from the group consisting of a carboxyl group, a hydroxyl group, a sulfonic acid group and a secondary amino group, or an aromatic group which comprises a secondary amino group and may comprise nitrogen; Rin the general formula (III) represents an aromatic amino acid residue represented by the general formula (III-1) below; X represents &#x2014;CHY&#x2014;(CH)Z; and Y and Z are respectively &#x2014;H or &#x2014;OH or together form a single bond: (III-1) wherein Rrepresents a hydroxyl group which may be present or absent; and n represents an integer of 0 or 1. 

The present invention provides an affinity trap reactor that enables the reaction between an enzyme bound to a support and substrate to proceed efficiently without its applications being restricted by the type of enzyme and substrate used. The present invention relates to an affinity trap reactor composed of a support bound with an enzyme and a molecule that specifically binds with a substrate of the enzyme, and a single-stage process for obtaining BL-angiostatin from plasminogen contained in a biological sample, wherein a biological sample containing plasminogen is applied to an affinity trap reactor composed of a support bound with bacillolysin MA and lysine, and reacted under conditions of a temperature of 0 to 50&#xb0; C. in the presence of isopropyl alcohol but in the absence of calcium ions.

Affinity trap reactor and single-step process for purifying angiostatin-like fragment from human plasma using the same

Growing community of inventors

Inagi, Japan

Keiji Hasumi